141 related articles for article (PubMed ID: 10780912)
21. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.
Sion-Vardy N; Vardy D; Rodeck U; Kari C; Levin RM; Malkowicz SB
J Surg Res; 1995 Dec; 59(6):675-80. PubMed ID: 8538164
[TBL] [Abstract][Full Text] [Related]
22. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
El-Obeid A; Hesselager G; Westermark B; Nistér M
Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
[TBL] [Abstract][Full Text] [Related]
23. Tyrphostins are inhibitors of guanylyl and adenylyl cyclases.
Jaleel M; Shenoy AR; Visweswariah SS
Biochemistry; 2004 Jun; 43(25):8247-55. PubMed ID: 15209521
[TBL] [Abstract][Full Text] [Related]
24. Protein binding modulates inhibition of the epidermal growth factor receptor kinase and DNA synthesis by tyrphostins.
Hoffman R; Dennis IF; Donaldson J
Cancer Chemother Pharmacol; 1995; 36(4):316-24. PubMed ID: 7628051
[TBL] [Abstract][Full Text] [Related]
25. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
26. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A
Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro.
Partik G; Hochegger K; Schörkhuber M; Marian B
J Cancer Res Clin Oncol; 1999 Jul; 125(7):379-88. PubMed ID: 10394957
[TBL] [Abstract][Full Text] [Related]
28. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
Cassinelli G; Lanzi C; Pensa T; Gambetta RA; Nasini G; Cuccuru G; Cassinis M; Pratesi G; Polizzi D; Tortoreto M; Zunino F
Biochem Pharmacol; 2000 Jun; 59(12):1539-47. PubMed ID: 10799650
[TBL] [Abstract][Full Text] [Related]
29. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers.
Dvir A; Milner Y; Chomsky O; Gilon C; Gazit A; Levitzki A
J Cell Biol; 1991 May; 113(4):857-65. PubMed ID: 1709168
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression.
Theodorescu D; Laderoute KR; Calaoagan JM; Guilding KM
Int J Cancer; 1998 Dec; 78(6):775-82. PubMed ID: 9833772
[TBL] [Abstract][Full Text] [Related]
31. Activation of the mitogen-activated protein kinase cascade by tyrphostin (RG 50864).
Agbotounou WK; Mousset S; Piperno S; Pierre M; Jacquemin-Sablon A; Pierre J
Biochem Pharmacol; 1994 Aug; 48(3):505-15. PubMed ID: 8068037
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
Gillespie J; Dye JF; Schachter M; Guillou PJ
Br J Cancer; 1993 Dec; 68(6):1122-6. PubMed ID: 8260363
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Asslan R; Pradines A; Pratx C; Allal C; Favre G; Le Gaillard F
Biochem Biophys Res Commun; 1999 Jul; 260(3):699-706. PubMed ID: 10403829
[TBL] [Abstract][Full Text] [Related]
35. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
Gazit A; Yaish P; Gilon C; Levitzki A
J Med Chem; 1989 Oct; 32(10):2344-52. PubMed ID: 2552117
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties.
Brunton VG; Lear MJ; Robins DJ; Williamson S; Workman P
Anticancer Drug Des; 1994 Aug; 9(4):291-309. PubMed ID: 7916898
[TBL] [Abstract][Full Text] [Related]
37. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide).
Rewcastle GW; Palmer BD; Dobrusin EM; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1994 Jun; 37(13):2033-42. PubMed ID: 8027985
[TBL] [Abstract][Full Text] [Related]
39. Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro.
Seckl MJ; Rozengurt E
Eur J Cancer; 1996 Feb; 32A(2):342-5. PubMed ID: 8664052
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
